Beyond Meat Posts Mixed Results; CRISPR Therapeutics Tops Estimates
- August 08th, 2023
- 351 views
Beyond Meat, Inc. (Nasdaq: BYND) has reported a second-quarter 2023 loss of $0.83 per share, slightly better than the consensus estimated loss of $0.86 per share. However, quarterly revenues of $102.10 million fell short of the analysts' projected $108.40 million mark.
The company has revised its full-year 2023 outlook, forecasting net revenues within the range of approximately $360 million to $380 million, down from the prior projection of $375 million to $415 million. The consensus estimate for the period stands at $388.04 million in revenue.
$BYND was trading at $13.49 in after-hours, showing a decrease of $1.79 (-11.71%)
In other news, CRISPR Therapeutics AG (Nasdaq: CRSP) has announced its second-quarter 2023 financial results, revealing a loss of $0.98 per share and revenues of $70.0 million. These figures surpassed market consensus estimates, which had anticipated a loss of $2.12 per share on revenue of $1.71 million.
In after-hours, $CRSP was trading at $49.10, up $0.76 (+1.57%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login